84 related articles for article (PubMed ID: 16870974)
1. Effect of subjective reasoning and neurocognition on medication adherence for persons with schizophrenia.
Maeda K; Kasai K; Watanabe A; Henomatsu K; Rogers MA; Kato N
Psychiatr Serv; 2006 Aug; 57(8):1203-5. PubMed ID: 16870974
[TBL] [Abstract][Full Text] [Related]
2. Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia.
El-Missiry A; Elbatrawy A; El Missiry M; Moneim DA; Ali R; Essawy H
J Psychiatr Res; 2015 Nov; 70():106-12. PubMed ID: 26424429
[TBL] [Abstract][Full Text] [Related]
3. Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia.
Sapra M; Vahia IV; Reyes PN; Ramirez P; Cohen CI
Schizophr Res; 2008 Dec; 106(2-3):348-55. PubMed ID: 18851906
[TBL] [Abstract][Full Text] [Related]
4. Association between attitude toward medication and neurocognitive function in schizophrenia.
Kim SW; Shin IS; Kim JM; Yang SJ; Shin HY; Yoon JS
Clin Neuropharmacol; 2006; 29(4):197-205. PubMed ID: 16855421
[TBL] [Abstract][Full Text] [Related]
5. [Influence of attention on an auditory-verbal learning test in schizophrenic patients].
Huguelet P; Nicastro R; Zanello A
Encephale; 2002; 28(4):291-7. PubMed ID: 12232538
[TBL] [Abstract][Full Text] [Related]
6. Reasons for adherence and nonadherence: a pilot study comparing first- and multi-episode schizophrenia patients.
Sapra M; Weiden PJ; Schooler NR; Sunakawa-McMillan A; Uzenoff S; Burkholder P
Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):199-206. PubMed ID: 23428784
[TBL] [Abstract][Full Text] [Related]
7. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
8. Predictors of medication adherence in patients with schizophrenia and bipolar disorder.
Jónsdóttir H; Opjordsmoen S; Birkenaes AB; Simonsen C; Engh JA; Ringen PA; Vaskinn A; Friis S; Sundet K; Andreassen OA
Acta Psychiatr Scand; 2013 Jan; 127(1):23-33. PubMed ID: 22900964
[TBL] [Abstract][Full Text] [Related]
9. Understanding adherence to neuroleptic treatment in schizophreniaí.
Vauth R; Löschmann C; Rüsch N; Corrigan PW
Psychiatry Res; 2004 Apr; 126(1):43-9. PubMed ID: 15081626
[TBL] [Abstract][Full Text] [Related]
10. Treatment adherence and insight in schizophrenia.
Bitter I; Fehér L; Tényi T; Czobor P
Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic medication and cognitive function in schizophrenia.
Hori H; Noguchi H; Hashimoto R; Nakabayashi T; Omori M; Takahashi S; Tsukue R; Anami K; Hirabayashi N; Harada S; Saitoh O; Iwase M; Kajimoto O; Takeda M; Okabe S; Kunugi H
Schizophr Res; 2006 Sep; 86(1-3):138-46. PubMed ID: 16793238
[TBL] [Abstract][Full Text] [Related]
12. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
Löffler W; Kilian R; Toumi M; Angermeyer MC
Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
[TBL] [Abstract][Full Text] [Related]
13. [Neurocognitive function in clinically stable patients with schizophrenia or bipolar disorder and normal controls].
Konstantakopoulos G; Ioannidi N; Patrikelis P; Soumani A; Oulis P; Sakkas D; Papadimitriou GN; Ploumpidis D
Psychiatriki; 2011; 22(3):195-206. PubMed ID: 21971195
[TBL] [Abstract][Full Text] [Related]
14. The influence of sex on cognitive insight and neurocognitive functioning in schizophrenia.
Kao YC; Liu YP; Lien YJ; Lin SJ; Lu CW; Wang TS; Loh CH
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jul; 44():193-200. PubMed ID: 23419242
[TBL] [Abstract][Full Text] [Related]
15. Neurocognitive functioning in a group of offspring genetically at high-risk for schizophrenia in Eastern Turkey.
Ozan E; Deveci E; Oral M; Karahan U; Oral E; Aydin N; Kirpinar I
Brain Res Bull; 2010 May; 82(3-4):218-23. PubMed ID: 20435102
[TBL] [Abstract][Full Text] [Related]
16. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand.
Maneesakorn S; Robson D; Gournay K; Gray R
J Clin Nurs; 2007 Jul; 16(7):1302-12. PubMed ID: 17584349
[TBL] [Abstract][Full Text] [Related]
17. Cognitive and clinical factors are associated with service engagement in early-phase schizophrenia spectrum disorders.
Johansen R; Hestad K; Iversen VC; Agartz I; Sundet K; Andreassen OA; Melle I
J Nerv Ment Dis; 2011 Mar; 199(3):176-82. PubMed ID: 21346488
[TBL] [Abstract][Full Text] [Related]
18. Neurocognitive correlates of response to treatment in formal thought disorder in patients with first-episode schizophrenia.
Goldstein RZ; Giovannetti T; Schullery M; Zuffante PA; Lieberman JA; Robinson DG; Barr WB; Bilder RM
Neuropsychiatry Neuropsychol Behav Neurol; 2002 Jun; 15(2):88-98. PubMed ID: 12050471
[TBL] [Abstract][Full Text] [Related]
19. Relationships among medication adherence, insight, and neurocognition in chronic schizophrenia.
Na E; Yim SJ; Lee JN; Kim JM; Hong K; Hong MH; Han H
Psychiatry Clin Neurosci; 2015 May; 69(5):298-304. PubMed ID: 25600955
[TBL] [Abstract][Full Text] [Related]
20. Demographic, clinical, and neurocognitive predictors of quality of life in schizophrenia patients receiving conventional neuroleptics.
Sota TL; Heinrichs RW
Compr Psychiatry; 2004; 45(5):415-21. PubMed ID: 15332206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
